Rhythm Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David Meeker
- Full Time Employees
- 414
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 222 Berkeley Street Boston MA United States of America 02116
- IPO Date
- Oct 9, 2017
- CIK
- 0001649904
- Website
- rhythmtx.com
- Similar Companies
- Business
- Rhythm Pharmaceuticals, Inc. Rhythm Pharmaceuticals, Inc. (RYTM) is a commercial-stage biopharmaceutical company focused on developing and commercializing precision medicines for rare neuroendocrine diseases, particularly those involving melanocortin-4 receptor (MC4R) pathway disorders that cause hyperphagia and severe obesity. The company's lead product, IMCIVREE (setmelanotide), an MC4R agonist, is approved by the FDA and European Commission for chronic weight management in patients with obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency, as well as Bardet-Biedl syndrome (BBS); it targets root causes of insatiable hunger and early-onset obesity in these genetic conditions. Rhythm advances a pipeline including earlier-stage MC4R agonists such as RM-718 for weekly subcutaneous administration, bivamelagon (LB54640), an oral small molecule now in Phase 2 trials for acquired hypothalamic obesity following completion of enrollment, and setmelanotide expansions into Phase 3 trials for acquired hypothalamic obesity, Prader-Willi syndrome, and other MC4R-related disorders like POMC/LEPR heterozygous deficiency, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, and Alström syndrome. Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals operates primarily in the United States and Europe, with over 250 employees across North America and Europe; it generates revenue mainly from U.S. IMCIVREE sales, supplemented by international ex-U.S. growth and partnerships. The company maintains licensing and collaboration agreements with LG Chem, Ltd., Ipsen Pharma S.A.S., Camurus, RareStone Group Ltd., and Axovia Therapeutics to support global development and commercialization of its therapies. Recent developments include the 2023 acquisition of Xinvento and initiation of a Phase 3 trial in acquired hypothalamic obesity; the 2024 acquisition of oral MC4R agonist LB54640 from LG Chem Life Sciences and first patient dosing with RM-718; a January 2025 strategic partnership with Trispera Pharma Solutions in Turkey; a March 2025 research collaboration with the Raymond A. Wood Foundation on craniopharyngioma-related fatigue; enrollment completion in the Phase 2 bivamelagon trial with topline data expected in Q3 2025; and anticipated topline Phase 3 data in hypothalamic obesity in Q2 2025, alongside regulatory submissions and new trial enrollments in congenital hypothalamic obesity and Prader-Willi syndrome.
Company News
Here Are Friday’s Top Wall Street Analyst Research Calls: Baozun, Commerce Bancshares, Element Solutions, Evolution Petroleum, Petrobras, Rythm Pharmaceuticals, Terawulf, UMB Financial, Workday, and More
Bank of New York Mellon Corp Purchases Shares of 394,044 Rhythm Pharmaceuticals, Inc. $RYTM
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?
Rhythm Pharmaceuticals Q2 Earnings Call Highlights
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript
Rhythm Pharmaceuticals Q2 Earnings Call Highlights
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Here Are Monday’s Top Wall Street Analyst Research Calls: Alphabet, Clean Harbors, Ford, Huntington Bancshares, Rivian, Rocket Lab, Terawulf, Vale, Warner Bros. Discovery, and More
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm